Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-24-046026
Filing Date
2024-11-14
Accepted
2024-11-14 17:00:58
Documents
65
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 2855400
2 ex31-1.htm EX-31.1 18551
3 ex31-2.htm EX-31.2 18289
4 ex32-1.htm EX-32.1 7905
5 ex32-2.htm EX-32.2 7867
  Complete submission text file 0001493152-24-046026.txt   10892210

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE mymd-20240930.xsd EX-101.SCH 66339
7 XBRL CALCULATION FILE mymd-20240930_cal.xml EX-101.CAL 56296
8 XBRL DEFINITION FILE mymd-20240930_def.xml EX-101.DEF 316897
9 XBRL LABEL FILE mymd-20240930_lab.xml EX-101.LAB 540351
10 XBRL PRESENTATION FILE mymd-20240930_pre.xml EX-101.PRE 418555
68 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 1982513
Mailing Address 855 N. WOLFE STREET SUITE 601 BALTIMORE MD 21205
Business Address 855 N. WOLFE STREET SUITE 601 BALTIMORE MD 21205 856-848-8698
TNF Pharmaceuticals, Inc. (Filer) CIK: 0001321834 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36268 | Film No.: 241463996
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)